About Profound Bio
Profound Bio is a company based in Woodinville (United States) founded in 2018 was acquired by Genmab in April 2024. Profound Bio has raised $237 million across 3 funding rounds from investors including Genmab, T. Rowe Price and Citadel. Profound Bio operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Woodinville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Profoundbio Us Co
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Profound Bio
Profound Bio has successfully raised a total of $237M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $112 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Profound Bio
Profound Bio has secured backing from 21 investors, including venture fund and institutional investors. Prominent investors backing the company include Genmab, T. Rowe Price and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Profound Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Profound Bio
Investment portfolio details for Profound Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Profound Bio
Detailed financials for Profound Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Profound Bio Comparisons
Peer comparison for Profound Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Profound Bio
Profound Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Profound Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Profound Bio
Complete news archive for Profound Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Profound Bio
Profound Bio was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Profound Bio is headquartered in Woodinville, United States. It is registered at Woodinville, Washington, United States.
Baiteng Zhao is the current CEO of Profound Bio.
Profound Bio is a funded company, having raised a total of $237M across 3 funding rounds to date.
Profound Bio was founded in 2018 and is based in Woodinville, United States. Operations focus on the biotechnology sector, where novel therapies for cancer treatment are developed. Emphasis is placed on chemistry, manufacturing, and controls (CMC) for antibody-drug conjugates. These conjugates are engineered to target and kill tumor cells, promote cell rejuvenation, stimulate collagen production, and inhibit collagen degradation processes.
Profound Bio's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Profound Bio has 21 investors. Key investors include Genmab, T. Rowe Price, Citadel, Orbimed, and Janus Henderson Investors.